<DOC>
	<DOCNO>NCT01074268</DOCNO>
	<brief_summary>This trial conduct Asia , Europe , Japan South America . The aim trial compare efficacy , safety tolerability NN1250 ( insulin degludec ( [ Deg ] ) insulin detemir ( IDet ) , combine insulin aspart . The main period register internally Novo Nordisk NN1250-3585 extension period register NN1250-3725 .</brief_summary>
	<brief_title>Comparison NN1250 Plus Insulin Aspart With Insulin Detemir Plus Insulin Aspart Type 1 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec , insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Detemir</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<criteria>Type 1 diabetes mellitus least 12 month Current treatment basal bolus insulin least 12 month HbA1c equal 10.0 % Body Mass Index ( BMI ) equal 35.0 kg/m^2 For Japan : Minimum age 20 year For extension trial : Completed sixmonth treatment period trial NN12503585 ( NCT01074268 ) Use antidiabetic drug insulin within last 3 month Cardiovascular disease within last 6 month Uncontrolled treated/untreated severe hypertension Recurrent severe hypoglycemia hypoglycemic unawareness hospitalisation diabetic ketoacidosis previous 6 month Pregnancy , breastfeeding , intention become pregnant use adequate contraceptive measure Cancer medical history cancer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>